Effectiveness of tofacitinib versus tumor necrosis factor inhibitors and in those receiving tofacitinib as different lines of therapy in patients with rheumatoid arthritis: results from the United States CorEvitas Rheumatoid Arthritis Registry.

Objectives: To compare effectiveness of tofacitinib versus tumor necrosis factor inhibitors (TNFi), and across tofacitinib lines of therapy, in patients with rheumatoid arthritis (RA), using US CorEvitas RA Registry data.

Methods: Analysis included patients with RA initiating tofacitinib or TNFi with a 12-month follow-up visit between November 2012-February 2021. Primary (Clinical Disease Activity Index-defined low disease activity [CDAI-LDA: CDAI ≤ 10]) and secondary (clinical/disease activity/patient-reported) effectiveness outcomes were assessed at month 12.

Impact of Age on Rheumatic Immune-related Adverse Events: Experience from the Canadian Research Group of Rheumatology in Immuno-Oncology (CanRIO).

Objective: Immune checkpoint inhibitors (ICI) have revolutionized cancer outcomes but are limited by immunerelated adverse events (irAE), including rheumatic irAEs (Rh-irAE). Aging is associated with increased inflammation, referred to as "inflamm-aging". In this study, we explore the impact of age on severity, frequency, and treatment of Rh-irAEs.

Cefiderocol pharmacokinetics during acute pulmonary exacerbations in hospitalized adult persons with cystic fibrosis.

Persons with CF (pwCF) present altered pharmacokinetics (PK) and are often infected with multidrug-resistant (MDR) bacteria. Herein, we describe the PK of cefiderocol, a siderophore cephalosporin with potent activity against MDR Gram-negative rods, in hospitalized adult pwCF with acute pulmonary exacerbation (APE). PwCF received ≥3 doses of 2 g cefiderocol (3 h infusion) with frequency determined according to their estimated glomerular filtration rate (eGFR).

Health misinformation: protocol for a hybrid concept analysis and development.

Background: Misinformation represents a serious and growing concern for public health and healthcare health; and has attracted much interest from researchers, media, and the public over recent years. Despite increased concern about the impacts of misinformation on health and wellbeing, however, the concept of health misinformation remains underdeveloped. In particular, there is a need to clarify how certain types of health information come to be designated as "misinformation," what characteristics are associated with this classification, and how the concept of misinformation is applied in health contexts.

Invasive Inguinal Lymph Node Recurrence of a Perineal Rhabdomyosarcoma.

Rhabdomyosarcoma (RMS) is an aggressive soft tissue sarcoma derived from embryonic mesenchymal tissue. RMS can be found anywhere in the body, including the head and neck, extremities, pelvis, and genitourinary tract. Perineal-RMS is a rare and aggressive form of RMS.